Literature DB >> 25343066

Primary sclerosing cholangitis as an intractable disease.

Sumihito Tamura1, Yasuhiko Sugawara1, Norihiro Kokudo1.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown origin which eventually results in liver cirrhosis. The disease is reported to be more common among the Western population than in the Asian population. Asian experience remains limited. Diagnosis and treatment standards in the Far East have largely followed those in the West, including liver transplantation. Unlike in the West, however, recent reports from Japan have presented with a higher recurrence rate of PSC after liver transplantation, suggesting the intractable nature of the disease even after the replacement of the entire affected organ.

Entities:  

Keywords:  Japan; Primary sclerosing cholangitis (PSC); deceased donor liver transplantation (DDLT); living donor liver transplantation (LDLT)

Year:  2012        PMID: 25343066      PMCID: PMC4204589          DOI: 10.5582/irdr.2012.v1.1.13

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  45 in total

1.  Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease.

Authors:  R Sheng; W L Campbell; A B Zajko; R L Baron
Journal:  AJR Am J Roentgenol       Date:  1996-05       Impact factor: 3.959

Review 2.  Primary sclerosing cholangitis.

Authors:  Y M Lee; M M Kaplan
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

3.  Primary sclerosing cholangitis in Japan--analysis of 192 cases.

Authors:  H Takikawa; T Manabe
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

4.  Selection of liver-transplant candidates for adult-to-adult living donor liver transplantation as the only surgical option for end-stage liver disease.

Authors:  Noriyo Yamashiki; Yasuhiko Sugawara; Sumihito Tamura; Junichi Kaneko; Kayo Nojiri; Masao Omata; Masatoshi Makuuchi
Journal:  Liver Transpl       Date:  2006-07       Impact factor: 5.799

Review 5.  Technical advances in living-related liver transplantation.

Authors:  Y Sugawara; M Makuuchi
Journal:  J Hepatobiliary Pancreat Surg       Date:  1999

6.  Adult-to-adult living donor liver transplantation at the Asan Medical Center.

Authors:  Deok-Bog Moon; Sung-Gyu Lee
Journal:  Yonsei Med J       Date:  2004-12-31       Impact factor: 2.759

7.  Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC.

Authors:  Anurag Maheshwari; Hwan Y Yoo; Paul J Thuluvath
Journal:  Am J Gastroenterol       Date:  2004-03       Impact factor: 10.864

8.  Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation.

Authors:  Jacob Alexander; James D Lord; Matthew M Yeh; Carlos Cuevas; Ramasamy Bakthavatsalam; Kris V Kowdley
Journal:  Liver Transpl       Date:  2008-02       Impact factor: 5.799

9.  A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts.

Authors:  Edward Alabraba; Peter Nightingale; Bridget Gunson; Stefan Hubscher; Simon Olliff; Darius Mirza; James Neuberger
Journal:  Liver Transpl       Date:  2009-03       Impact factor: 5.799

10.  Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis.

Authors:  Giovanni Varotti; Gabriel E Gondolesi; Sasan Roayaie; Arief Suriawinata; Kyle Soltys; Thomas M Fishbein; Myron E Schwartz; Charles Miller
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

View more
  1 in total

1.  Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis.

Authors:  Lukas Bajer; Miloslav Kverka; Martin Kostovcik; Peter Macinga; Jiri Dvorak; Zuzana Stehlikova; Jan Brezina; Pavel Wohl; Julius Spicak; Pavel Drastich
Journal:  World J Gastroenterol       Date:  2017-07-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.